

Mike Sweeney first joined Pfizer in 1997 as a microbiologist contributing to susceptibility and drug combination projects that helped advance linezolid (Zyvox®) to FDA approval in 2000. In 2003 he joined Pfizer Animal Health and contributed to the development of products such as tulathromycin (Draxxin®) and the ceftiofur family. His laboratory experience includes *in vitro* and *in vivo* susceptibility testing per Clinical and Laboratory Standards methods, molecular techniques, and drug surveillance of Pfizer antimicrobial products. He is author or co-author on 18 posters, 19 peer-reviewed journal articles and one book chapter. Currently, he is the project team leader for Antibacterial Leadseeking discovery activities. His interests outside of work include playing the guitar and serving as a mentor for Big Brothers Big Sisters.